New York State Teachers Retirement System Reduces Stake in Hologic, Inc. (NASDAQ:HOLX)

New York State Teachers Retirement System lowered its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 8.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 185,321 shares of the medical equipment provider's stock after selling 18,020 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Hologic worth $11,447,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Geode Capital Management LLC increased its position in shares of Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after purchasing an additional 144,838 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after purchasing an additional 129,035 shares during the period. Invesco Ltd. increased its position in shares of Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after purchasing an additional 572,187 shares during the period. Boston Partners increased its position in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. Finally, Northern Trust Corp increased its position in shares of Hologic by 26.9% in the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after purchasing an additional 668,086 shares during the period. Institutional investors own 94.73% of the company's stock.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the transaction, the director owned 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.88% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently weighed in on HOLX shares. Stephens reduced their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Royal Bank Of Canada reduced their price objective on Hologic from $75.00 to $70.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic currently has an average rating of "Hold" and a consensus price target of $77.42.

Hologic Stock Down 0.9%

Shares of NASDAQ:HOLX traded down $0.57 during mid-day trading on Friday, hitting $64.74. 1,233,581 shares of the company traded hands, compared to its average volume of 2,378,982. The stock has a market cap of $14.43 billion, a P/E ratio of 27.31, a P/E/G ratio of 2.37 and a beta of 0.55. The company has a current ratio of 3.24, a quick ratio of 2.52 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The stock has a 50-day moving average price of $60.71 and a two-hundred day moving average price of $63.70.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the prior year, the firm earned $1.03 EPS. The business's revenue for the quarter was down 1.2% compared to the same quarter last year. On average, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.